Hangzhou Nuanxinjia Electronic Technology Co., Ltd. has completed a Series C+ financing round of RMB 500 million—its second funding round this year—bringing its cumulative financing to RMB 1 billion. The company has achieved global leadership in the core track of visual reconstruction brain-computer interfaces, securing China's first GCP clinical trial for a high-resolution retinal pathway visual brain-computer interface. It has completed three related clinical trials, with subjects recovering far faster than international norms. The company has innovatively laid out a dual-track parallel approach combining the retinal pathway and the visual cortex pathway. Leveraging a full-stack, self-developed technology system built since 2014, its 320-channel retinal visual brain-computer interface has entered the GCP standardized clinical trial stage, while its 1,280-channel visual cortex visual brain-computer interface product is in the R&D stage. With continued technological iteration, vision is expected to become an upgradable sense, expanding the boundaries of human perception. Multiple investors in this round are optimistic about Nuanxinjia's technological strength and the value of its track, and will support the company in bringing products to market to benefit the visually impaired.